×
S&P 500   3,891.23 (+1.20%)
DOW   31,322.55 (+0.92%)
QQQ   293.73 (+1.71%)
AAPL   145.54 (+1.83%)
MSFT   267.82 (+0.60%)
META   171.40 (+0.96%)
GOOGL   2,348.01 (+2.47%)
AMZN   115.99 (+1.45%)
TSLA   726.34 (+4.48%)
NVDA   157.60 (+4.16%)
NIO   22.28 (+6.96%)
BABA   123.30 (+3.51%)
AMD   79.11 (+4.99%)
MU   58.46 (+1.90%)
CGC   2.69 (+1.51%)
T   21.14 (+0.24%)
GE   62.32 (+1.22%)
F   11.55 (+4.43%)
DIS   97.05 (+1.01%)
AMC   13.73 (+9.23%)
PFE   53.07 (+0.61%)
PYPL   74.86 (+2.21%)
NFLX   189.61 (+3.02%)
S&P 500   3,891.23 (+1.20%)
DOW   31,322.55 (+0.92%)
QQQ   293.73 (+1.71%)
AAPL   145.54 (+1.83%)
MSFT   267.82 (+0.60%)
META   171.40 (+0.96%)
GOOGL   2,348.01 (+2.47%)
AMZN   115.99 (+1.45%)
TSLA   726.34 (+4.48%)
NVDA   157.60 (+4.16%)
NIO   22.28 (+6.96%)
BABA   123.30 (+3.51%)
AMD   79.11 (+4.99%)
MU   58.46 (+1.90%)
CGC   2.69 (+1.51%)
T   21.14 (+0.24%)
GE   62.32 (+1.22%)
F   11.55 (+4.43%)
DIS   97.05 (+1.01%)
AMC   13.73 (+9.23%)
PFE   53.07 (+0.61%)
PYPL   74.86 (+2.21%)
NFLX   189.61 (+3.02%)
S&P 500   3,891.23 (+1.20%)
DOW   31,322.55 (+0.92%)
QQQ   293.73 (+1.71%)
AAPL   145.54 (+1.83%)
MSFT   267.82 (+0.60%)
META   171.40 (+0.96%)
GOOGL   2,348.01 (+2.47%)
AMZN   115.99 (+1.45%)
TSLA   726.34 (+4.48%)
NVDA   157.60 (+4.16%)
NIO   22.28 (+6.96%)
BABA   123.30 (+3.51%)
AMD   79.11 (+4.99%)
MU   58.46 (+1.90%)
CGC   2.69 (+1.51%)
T   21.14 (+0.24%)
GE   62.32 (+1.22%)
F   11.55 (+4.43%)
DIS   97.05 (+1.01%)
AMC   13.73 (+9.23%)
PFE   53.07 (+0.61%)
PYPL   74.86 (+2.21%)
NFLX   189.61 (+3.02%)
S&P 500   3,891.23 (+1.20%)
DOW   31,322.55 (+0.92%)
QQQ   293.73 (+1.71%)
AAPL   145.54 (+1.83%)
MSFT   267.82 (+0.60%)
META   171.40 (+0.96%)
GOOGL   2,348.01 (+2.47%)
AMZN   115.99 (+1.45%)
TSLA   726.34 (+4.48%)
NVDA   157.60 (+4.16%)
NIO   22.28 (+6.96%)
BABA   123.30 (+3.51%)
AMD   79.11 (+4.99%)
MU   58.46 (+1.90%)
CGC   2.69 (+1.51%)
T   21.14 (+0.24%)
GE   62.32 (+1.22%)
F   11.55 (+4.43%)
DIS   97.05 (+1.01%)
AMC   13.73 (+9.23%)
PFE   53.07 (+0.61%)
PYPL   74.86 (+2.21%)
NFLX   189.61 (+3.02%)

Compass Therapeutics Stock Forecast, Price & News

$2.82
-0.06 (-2.08%)
(As of 07/7/2022 11:19 AM ET)
Add
Compare
Today's Range
$2.82
$2.89
50-Day Range
$1.43
$3.10
52-Week Range
$1.25
$5.40
Volume
531 shs
Average Volume
194,162 shs
Market Capitalization
$285.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.86

Compass Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
254.6% Upside
$10.00 Price Target
Short Interest
Healthy
0.15% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$828,278 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.35) to ($0.56) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.09 out of 5 stars

Medical Sector

417th out of 1,433 stocks

Biological Products, Except Diagnostic Industry

67th out of 220 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive CMPX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Compass Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Compass Therapeutics logo

About Compass Therapeutics (NASDAQ:CMPX) Stock

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops proprietary antibody-based therapeutics to treat multiple human diseases. The company's product candidates include CTX-009, an investigational bispecific antibody, which is in Phase II clinical trial for biliary tract cancers, as well as Phase Ib clinical trial for colorectal and ovarian cancer; CTX-471, a monoclonal antibody product candidate that is in Phase I clinical trial for patients with solid tumors, such as small cell lung cancer and melanoma; and CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 for oncology area. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

CMPX Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CMPX
Fax
N/A
Employees
24
Year Founded
N/A

Company Calendar

Last Earnings
5/09/2022
Today
7/07/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$10.00
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+249.5%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
8 Analysts

Profitability

Net Income
$-82,180,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.43 per share

Miscellaneous

Free Float
71,101,000
Market Cap
$285.61 million
Optionable
Not Optionable
Beta
N/A














Compass Therapeutics Frequently Asked Questions

Should I buy or sell Compass Therapeutics stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Compass Therapeutics in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Compass Therapeutics stock.
View analyst ratings for Compass Therapeutics
or view top-rated stocks.

What is Compass Therapeutics' stock price forecast for 2022?

8 Wall Street analysts have issued 1-year price objectives for Compass Therapeutics' stock. Their CMPX stock forecasts range from $5.00 to $15.00. On average, they expect Compass Therapeutics' stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 254.6% from the stock's current price.
View analysts' price targets for Compass Therapeutics
or view top-rated stocks among Wall Street analysts.

How has Compass Therapeutics' stock price performed in 2022?

Compass Therapeutics' stock was trading at $3.00 on January 1st, 2022. Since then, CMPX stock has decreased by 6.0% and is now trading at $2.82.
View the best growth stocks for 2022 here
.

How were Compass Therapeutics' earnings last quarter?

Compass Therapeutics, Inc. (NASDAQ:CMPX) posted its quarterly earnings results on Monday, May, 9th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.07.
View Compass Therapeutics' earnings history
.

Who are Compass Therapeutics' key executives?

Compass Therapeutics' management team includes the following people:
  • Dr. Thomas J. Schuetz M.D., Ph.D., Co-Founder, CEO & Director (Age 61, Pay $454k)
  • Dr. Vered Bisker-Leib MBA, Ph.D., Pres & COO (Age 51, Pay $720k)
  • Dr. Susan Kalled Ph.D., Chief Scientific Officer (Age 61, Pay $445.5k)
  • Mr. Neil L. Lerner CPA, VP of Fin. (Age 55)
  • Mr. Jonathan Anderman J.D., VP, Head of Legal & Corp. Sec.
  • Anna Gifford, Communications Mang.
  • Dr. Peter F. Moesta Ph.D., Interim Head of CMC

When did Compass Therapeutics IPO?

(CMPX) raised $50 million in an IPO on the week of November 16th 2020. The company issued 9,000,000 shares at a price of $5.00-$6.00 per share. Citigroup, Credit Suisse and Stifel acted as the underwriters for the IPO and Raymond James was co-manager.

What is Compass Therapeutics' stock symbol?

Compass Therapeutics trades on the NASDAQ under the ticker symbol "CMPX."

How do I buy shares of Compass Therapeutics?

Shares of CMPX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Compass Therapeutics' stock price today?

One share of CMPX stock can currently be purchased for approximately $2.82.

How much money does Compass Therapeutics make?

Compass Therapeutics (NASDAQ:CMPX) has a market capitalization of $285.61 million.

How many employees does Compass Therapeutics have?

Compass Therapeutics employs 24 workers across the globe.

How can I contact Compass Therapeutics?

The official website for Compass Therapeutics is www.compasstherapeutics.com. The company can be reached via phone at 617-500-8099 or via email at ir@compasstherapeutics.com.

This page (NASDAQ:CMPX) was last updated on 7/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.